COVID-19 Impact on Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Icotinib
  • 1.4.3 Gefitinib
  • 1.4.4 Erlotinib
  • 1.4.5 Afatinib
  • 1.4.6 Osimertinib
  • 1.4.7 Brigatinib
  • 1.4.8 Other
• 1.5 Market by Application
  • 1.5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
  • 1.5.2 Squamous Cell Carcinoma of NSCLC
  • 1.5.3 Adenocarcinoma of NSCLC
  • 1.5.4 Large Cell Carcinoma of NSCLC
• 1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Targeted Drug EGFR RTK Inhibitors for NSCLC Industry
    • 1.6.1.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Targeted Drug EGFR RTK Inhibitors for NSCLC Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Targeted Drug EGFR RTK Inhibitors for NSCLC Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Perspective (2015-2026)
• 2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Regions
  • 2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Share by Regions (2015-2020)
  • 2.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Targeted Drug EGFR RTK Inhibitors for NSCLC Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Market Size
  • 3.1.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue (2015-2020)
  • 3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio
  • 3.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2019
• 3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served
• 3.4 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
• 3.5 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Type (2015-2020)
• 4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2021-2026)

5 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Application (2015-2026)

• 5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
• 5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
• 6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in North America (2019-2020)
• 6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
• 6.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
• 7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Europe (2019-2020)
• 7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
• 7.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

8 China

• 8.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
• 8.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in China (2019-2020)
• 8.3 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
• 8.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
• 9.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Japan (2019-2020)
• 9.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
• 9.4 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
• 10.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
• 10.4 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

11 India

• 11.1 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
• 11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in India (2019-2020)
• 11.3 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
• 11.4 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
• 12.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
• 12.4 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Beta Pharma
  • 13.1.1 Beta Pharma Company Details
  • 13.1.2 Beta Pharma Business Overview and Its Total Revenue
  • 13.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020))
  • 13.1.5 Beta Pharma Recent Development
• 13.2 AstraZeneca
  • 13.2.1 AstraZeneca Company Details
  • 13.2.2 AstraZeneca Business Overview and Its Total Revenue
  • 13.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.2.5 AstraZeneca Recent Development
• 13.3 Natco Pharma
  • 13.3.1 Natco Pharma Company Details
  • 13.3.2 Natco Pharma Business Overview and Its Total Revenue
  • 13.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.3.5 Natco Pharma Recent Development
• 13.4 Qilu Pharmaceutical
  • 13.4.1 Qilu Pharmaceutical Company Details
  • 13.4.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
  • 13.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.4.5 Qilu Pharmaceutical Recent Development
• 13.5 Genentech (Roche Group)
  • 13.5.1 Genentech (Roche Group) Company Details
  • 13.5.2 Genentech (Roche Group) Business Overview and Its Total Revenue
  • 13.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.5.5 Genentech (Roche Group) Recent Development
• 13.6 Mylan
  • 13.6.1 Mylan Company Details
  • 13.6.2 Mylan Business Overview and Its Total Revenue
  • 13.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.6.5 Mylan Recent Development
• 13.7 Teva
  • 13.7.1 Teva Company Details
  • 13.7.2 Teva Business Overview and Its Total Revenue
  • 13.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.7.5 Teva Recent Development
• 13.8 OSI Pharmaceuticals
  • 13.8.1 OSI Pharmaceuticals Company Details
  • 13.8.2 OSI Pharmaceuticals Business Overview and Its Total Revenue
  • 13.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.8.5 OSI Pharmaceuticals Recent Development
• 13.9 Glenmark Pharmaceuticals
  • 13.9.1 Glenmark Pharmaceuticals Company Details
  • 13.9.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
  • 13.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.9.5 Glenmark Pharmaceuticals Recent Development
• 13.10 Beacon Pharmaceuticals
  • 13.10.1 Beacon Pharmaceuticals Company Details
  • 13.10.2 Beacon Pharmaceuticals Business Overview and Its Total Revenue
  • 13.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 13.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 13.10.5 Beacon Pharmaceuticals Recent Development
• 13.11 Boehringer Ingelheim
  • 10.11.1 Boehringer Ingelheim Company Details
  • 10.11.2 Boehringer Ingelheim Business Overview and Its Total Revenue
  • 10.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.11.4 Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.11.5 Boehringer Ingelheim Recent Development
• 13.12 Pfizer
  • 10.12.1 Pfizer Company Details
  • 10.12.2 Pfizer Business Overview and Its Total Revenue
  • 10.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.12.4 Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.12.5 Pfizer Recent Development
• 13.13 ARIAD Pharmaceuticals (Takeda)
  • 10.13.1 ARIAD Pharmaceuticals (Takeda) Company Details
  • 10.13.2 ARIAD Pharmaceuticals (Takeda) Business Overview and Its Total Revenue
  • 10.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.13.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.13.5 ARIAD Pharmaceuticals (Takeda) Recent Development
• 13.14 Genvio Pharma Limited
  • 10.14.1 Genvio Pharma Limited Company Details
  • 10.14.2 Genvio Pharma Limited Business Overview and Its Total Revenue
  • 10.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.14.4 Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.14.5 Genvio Pharma Limited Recent Development
• 13.15 Drug International Limted
  • 10.15.1 Drug International Limted Company Details
  • 10.15.2 Drug International Limted Business Overview and Its Total Revenue
  • 10.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.15.4 Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.15.5 Drug International Limted Recent Development
• 13.16 Everest Pharmaceuticals
  • 10.16.1 Everest Pharmaceuticals Company Details
  • 10.16.2 Everest Pharmaceuticals Business Overview and Its Total Revenue
  • 10.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.16.4 Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.16.5 Everest Pharmaceuticals Recent Development
• 13.17 Incepta Pharmaceuticals Limited
  • 10.17.1 Incepta Pharmaceuticals Limited Company Details
  • 10.17.2 Incepta Pharmaceuticals Limited Business Overview and Its Total Revenue
  • 10.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.17.4 Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.17.5 Incepta Pharmaceuticals Limited Recent Development
• 13.18 Cipla Pharma
  • 10.18.1 Cipla Pharma Company Details
  • 10.18.2 Cipla Pharma Business Overview and Its Total Revenue
  • 10.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.18.4 Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.18.5 Cipla Pharma Recent Development
• 13.19 Dr Reddy's Laboratories
  • 10.19.1 Dr Reddy's Laboratories Company Details
  • 10.19.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue
  • 10.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.19.4 Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.19.5 Dr Reddy's Laboratories Recent Development
• 13.20 Zydus Cadila
  • 10.20.1 Zydus Cadila Company Details
  • 10.20.2 Zydus Cadila Business Overview and Its Total Revenue
  • 10.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.20.4 Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.20.5 Zydus Cadila Recent Development
• 13.21 Hetero Drugs
  • 10.21.1 Hetero Drugs Company Details
  • 10.21.2 Hetero Drugs Business Overview and Its Total Revenue
  • 10.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.21.4 Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.21.5 Hetero Drugs Recent Development
• 13.22 Intas Pharmaceuticals
  • 10.22.1 Intas Pharmaceuticals Company Details
  • 10.22.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
  • 10.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.22.4 Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.22.5 Intas Pharmaceuticals Recent Development
• 13.23 Alkem Laboratories
  • 10.23.1 Alkem Laboratories Company Details
  • 10.23.2 Alkem Laboratories Business Overview and Its Total Revenue
  • 10.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.23.4 Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.23.5 Alkem Laboratories Recent Development
• 13.24 RPG Life Sciences
  • 10.24.1 RPG Life Sciences Company Details
  • 10.24.2 RPG Life Sciences Business Overview and Its Total Revenue
  • 10.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.24.4 RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.24.5 RPG Life Sciences Recent Development
• 13.25 Fresenius Kabi India
  • 10.25.1 Fresenius Kabi India Company Details
  • 10.25.2 Fresenius Kabi India Business Overview and Its Total Revenue
  • 10.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 10.25.4 Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
  • 10.25.5 Fresenius Kabi India Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer